AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01691053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04811001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: TAGRISSO 40 mg film-coated tablets TAGRISSO 80 mg film-coated tablets
Study NCT04811001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Vizimpro 15 mg film-coated tablets Vizimpro 30 mg film-coated tablets Vizimpro 45 mg film-coated tablets
Study NCT00779311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Sorafenib will be administered daily starting day 1 at 200mg QOD at Dose Level 1; 200mg/day at Dose Level 2; 200mg BID (5 days on/ 2 days off) at Dose Level 3; 200mg BID at Dose Level 4; and 400mg BID at Dose Level 5.
Study NCT00779311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab will be administered as 5mg/kg IV on Day 1 of each treatment cycle.
Study NCT00779311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen
Description: The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days continuous infusion.
Study NCT00118911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
Study NCT00118911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation techniques and education about ADHD
Description: Participants are provided with education about ADHD, instruction in relaxation techniques, and support in applying relaxation techniques to ADHD symptoms.
Study NCT03159819 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-CLD18 T Cells
Description: Dose escalation will be applied in this study.
Study NCT01867866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Study NCT01867866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine
Description: 35 mg/m2, orally, single dose
Study NCT03909672 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cupping Therapy
Description: application of cupping therapy with two acrylic type 1 cups (4.5 cm internal diameter, Dong Yang ® brand) with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally
Study NCT03909672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cupping Therapy
Description: application of cupping therapy with two acrylic type 1 cups (4.5 cm internal diameter, Dong Yang ® brand) with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally
Study NCT03330041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast absorbing gut suture
Description: Fast absorbing surgical gut suture is a strand of collagenous material
Study NCT03790384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Patients receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG) with a 40 mg mitomycin instillation the day before .
Study NCT01259635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback auditory stimulation
Description: Whenever freezing episodes occures, a metronom sound will be heard.
Study NCT03606148 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SurePathTM
Description: In the liquid-phase cytology, a fine-aspirated sample is immediately inserted into a container containing a commercially available preservative solution without a separate slide-smearing procedure and immediately after the fine-needle aspiration.
Study NCT03395223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Administration of Methylene Blue to treat acquired methaemoglobinaemia
Study NCT02452268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIZ985
Description: Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks
Study NCT02452268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: • PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
Study NCT01379170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euthyrox (levothyroxine)
Description: A dose of 25 μg per day of Euthyrox® will be administered orally during the first week and will be increased to 50 μg per day during the second week and to 75-100 μg per day in the third week depending on TSH, free T4 and T3 concentrations monitored throughout the treatment period. Patients will be instructed to take Euthyrox® after an overnight fast, 30 min before breakfast in the morning daily. After 3 months, free T4 and total T3 concentration must be in the normal range (free T4: 8.0-26 pmol/l, T4: 60-140 nmol/l and T3 1.2 - 3.4 nmol/l) and TSH 0.4-2.5 mU/l.
Study NCT02755142 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gliolan
Study NCT03876145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal ovarian stimulation
Description: After obtaining informed consent to participate in the study, the subjects will be randomly divided into the following 4 groups: The group of minimal ovarian stimulation with rec-FSH or HMG. The group of mild ovarian stimulation with rec-FSH or HMG. In all 4 experimental groups, after reaching at least three follicles the size of 12 millimeters (mm), daily administration of 0.25 milligram (mg) Cetrotide (antagonist GnRH) will be started and after reaching at least three follicles the size of 17 mm, 500 microgram Ovitrelle (recombinant Human curionic gonadotropin) will be prescribed. 36 hours later, ovulation process will be done. On the day of Ovitrelle administration, serum levels of estradiol and progesterone will be also evaluated. Based on the patient's condition and the quality of obtained oocytes and embryos, 2 embryos will be transferred.
Study NCT01080144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Critical flicker frequency procedure
Description: After TIPS, patients will be followed during one year and the psychometric test and Critical flicker frequency procedure will be performed every 3 months
Study NCT04763590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: This study focuses on patients who are on a mechanical ventilator and who have been medically cleared to come off of it. The purpose of the study is to learn more about the possible influence of cognitive behavioral therapy in helping patients who are having some trouble getting off of the ventilator. Cognitive behavioral therapy is a highly effective intervention for anxiety and the investigators are evaluating whether cognitive behavioral therapy might be helpful in cases where it is difficult to come off of the ventilator.~Cognitive behavioral therapy is experimental for mechanical ventilation assistance as no research to date has evaluated whether it might be helpful.
Study NCT01862432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate skin-to-skin
Description: The newborn is place on his mother's chest, immediately (in the first minute of life), in order to allow complete skin-to-skin contact.
Study NCT02448316 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic surgery
Description: Through 2 portals profound for the fascia plantaris (deep-fascial) lateral and medial a heel-spur will be resected and the medial half of the fascia is released from its attachment to the calcaneus.~A mikroskopic X-ray sensitive pearle (Tantalum-pearle) will be inserted in the fascia in the proximal end of the distal part of the remaining fascia for measuring distance (resorbtion).~Three weeks after operation, the patients are instructed to start a specific training program. Training is supervised every third week by a physiotherapist (week 3,6,9,12 after operation), and daily training is carried out at home. Sutures are removed after 10 days,
Study NCT02448316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolon
Description: 1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
Study NCT02448316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidokaine
Description: 1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
Study NCT02448316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: the patient is instructed in reduction in impact. strength training 3 times weekly and stretching exercises daily are recommended.
Study NCT03997929 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 1.3 BETA D GLUCAN
Description: dosage of 1.3 BETA D GLUCAN in the peritoneal fluid obtained during surgery with the β-glucan test (Fujifilm Wako Chemicals, Osaka, Japan)
Study NCT02899741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 1000mg every day for 90 days
Study NCT00540306 — intervention group
Intervention type: DEVICE
Intervention: Diffuse Optical Spectroscopy
Description: Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
Study NCT04024072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% ophthalmic suspension
Description: Test product
Study NCT04024072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azopt 1% Ophthalmic Suspension
Description: Reference product
Study NCT03673696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA Capsule
Description: Capsule administered orally once daily
Study NCT03673696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule
Study NCT00769808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb 217z Excimer Laser
Description: LASIK correction of myopia and myopic astigmatism
Study NCT03438578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efficacy Safety Score monitoring
Description: According to data gathered from ESS and monitoring, the patients will receive needed care.
Study NCT02157246 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pimonidazole
Study NCT02157246 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: F-MISO PET
Study NCT02157246 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pCT
Study NCT02157246 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional MRI
Study NCT02157246 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Study NCT02157246 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Study NCT03212807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Investigational Medicinal Product
Study NCT03212807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Investigational Medicinal Product
Study NCT04066946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent therapy
Description: Micro current therapy is a therapy to treat humans / animals using electric current with amperages flowing in the μA range. The device offers 2 treatment methods: manual treatment, which requires manual input corresponding to the mentioned parameters, and automatic treatment which, depending on the clinical picture and the currently measured resistance between the electrodes, allows the device to automatically change the mentioned parameters. For this study the investigators use an automatic treatment with predefined settings. This automatic programme consists of a variation of 20 different frequency settings during 17 minutes. This programme is repeated one time which leads to a total treatment time of 34 minutes. The intensity setting for the treatment is between 200 and 350 µA. The treatment is applied 5x per week in the first 6 weeks. The treatment is stopped after six weeks.
Study NCT04066946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of Care consists of:~During the first two weeks:~* Histoacryl glue to close the surgical incisions.~* Suture strips to keep the wound closed.~* Isobetadine Dermicum as anti-septic treatment~* Dry wound dressings during the first 2 weeks.~* Tubigrip~From two weeks until three months:~• Hydration with hydrating crème 2x per day (not within 4 hours before microcurrent treatment.~From three months onwards:~• Silicone gel sheet.
Study NCT04066946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of Care consists of:~During the first two weeks:~* Histoacryl glue to close the surgical incisions.~* Suture strips to keep the wound closed.~* Isobetadine Dermicum as anti-septic treatment~* Dry wound dressings during the first 2 weeks.~* Tubigrip~From two weeks until three months:~• Hydration with hydrating crème 2x per day (not within 4 hours before microcurrent treatment.~From three months onwards:~• Silicone gel sheet.
Study NCT04035265 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood test
Description: Carpus and fingers of non-dominating hand MRI with gadolinium contrast
Study NCT04035265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: Carpus and fingers of non-dominating hand MRI with gadolinium contrast
Study NCT01838590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Study NCT01838590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT03148106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatosensory Electrical Stimulation
Description: We will put adhesive electrodes on the affected arm and connect it to a device that will deliver a gentle electrical stimulation to the hand and arm. The stimulation will last for different amounts of time, depending on the stimulation condition. This can be 30 minutes twice a day (1 hour apart), 1 hour continuously, 2 hours continuously, or 3 hours continuously. The stimulation conditions will also vary in stimulation strength. It is normal that some people may feel a tingling sensation, while others may feel nothing.
Study NCT01567891 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYESO-1c259 T cells
Description: Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion.
Study NCT04240106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib orally daily beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
Study NCT04240106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: Aromatase Inhibitors beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
Study NCT03938818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tu'Washindi intervention
Description: The intervention includes the following components:~1. PrEP sensitization for men (community level). These activities will aim to provide men with basic information about PrEP and will be used to prepare men for more effective engagement in Buddy Days, described below.~2. Buddy Days (partner level). Buddy days will target male partner engagement by inviting couples to attend a community-wide event with health screenings, and PrEP sensitization, which aim to facilitate further communications about PrEP and increase men's support for AGYW's PrEP use.~3. Adherence support clubs (individual and peer levels). Support clubs will provide a forum for AGYW to discuss challenges and successes around PrEP use in relationships, including in the context of partner violence. Participation in these groups is hypothesized to increase self-efficacy for PrEP use by reducing social isolation and providing additional positive role-modeling from peer leaders.
Study NCT03938818 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard of care will include PrEP delivery according to the usual DREAMS procedures, including attendance at routine Safe Space meetings and routine PrEP provision at the Safe Space, if applicable.
Study NCT00114127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: 60 mg duloxetine 1x per day
Study NCT00114127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 60 mg duloxetine 1x per day
Study NCT00114127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 60 mg duloxetine 1x per day + 60mg duloxetine 1x per day
Study NCT00114127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60mg placebo 1x per day
Study NCT00224081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate,
Description: Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions
Study NCT01828918 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: microRNAs
Study NCT01916707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dosing of enoxaparin for VTE prophylaxis
Study NCT01916707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dosing of enoxaparin for VTE prophylaxis
Study NCT01446679 — intervention group
Intervention type: DRUG
Intervention: atrovastatin
Description: oral
Study NCT01116687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally
Study NCT00421148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg/kg
Description: IV infusion
Study NCT00421148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 1 mg/kg
Description: IV infusion
Study NCT00421148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Description: IV infusion
Study NCT00421148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Description: IV infusion
Study NCT00421148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study NCT00421148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocuronium bromide
Description: IV infusion
Study NCT00421148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: IV infusion
Study NCT05834985 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches
Description: endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches
Study NCT03222674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
Description: Infusion of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
Study NCT04005586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Delivery Device (LDD)
Description: Study eye will undergo Light delivery Device treatments
Study NCT04224922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT04224922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatinum
Study NCT04224922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study NCT01116687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03345940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod
Description: Fingolimod is a currently approved oral DMT for the treatment of relapsing remitting MS. It modulates sphingosine-1 phosphate receptors.
Study NCT04224922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00761982 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Infusion on autologous CD34+ stem cells into middle cerebral artery
Description: Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients
Study NCT03345940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl Fumarate
Description: Dimethyl Fumarate is a currently approved oral DMT for the treatment of relapsing remitting MS. The mode of action comprises immunomodulatory effects and an activation of nuclear (erythroid-derived 2) related factor mediated antioxidative response pathways leading to additional cytoprotective effects.
Study NCT06580860 — intervention group
Intervention type: DRUG
Intervention: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Description: Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
Study NCT01762878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry powder for oral inhalation once daily using DIKUS device